Ezetimibe/simvastatin compared with atorvastatin or rosuvastatin in lowering to specified levels both LDL-C and each of five other emerging risk factors for coronary heart disease: Non–HDL-cholesterol, TC/HDL-C, apolipoprotein B, apo-B/apo-A-I, or C-reactive protein
To access this article, please choose from the options below
PII: S1933-2874(08)00889-1
doi:10.1016/j.jacl.2008.10.003
© 2008 Published by Elsevier Inc.
